Publications by authors named "Gie Tan"
Background & Aims: Two percent to 4% of all cases of colorectal cancer (CRC) are associated with Lynch syndrome. Dominant clustering of CRC (non-Lynch syndrome) accounts for 1%-3% of the cases. Because carcinogenesis is accelerated in Lynch syndrome, an intensive colonoscopic surveillance program has been recommended since 1995.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted to compare the effectiveness and safety of taking prolonged-release mesalamine once daily versus twice daily in patients with mild-to-moderate ulcerative colitis.
- The trial involved 362 patients and found that 70.9% of those taking 2 g once daily maintained remission after one year compared to 58.9% of those taking 1 g twice daily, showing significant improvement with the once-daily regimen.
- Additionally, adherence to therapy was better in the once-daily group, and overall side effects were similar between both dosing schedules, suggesting that once-daily mesalamine is a more effective and preferred option for maintaining remission in these patients.
Aim: To determine in a noninferiority study whether mesalamine foam is as effective as mesalamine liquid enema for inducing clinical remission in patients with active left-sided ulcerative colitis (UC).
Methods: In a multicenter investigator-blind trial, 375 patients with mild-to-moderate UC were randomized to receive mesalamine foam 1 g/80 mL/day or mesalamine liquid enema 1 g/100 mL/day for 4 wk (W). Inclusion criteria were: disease extension at least 5 cm from anorectal junction and not above splenic flexure and Clinical Activity Index (CAI) 1-4 > or = 4.